US 12,281,329 B2
Compositions and methods for immune cell modulation in adoptive immunotherapies
Jonathan Rosen, San Diego, CA (US); Betsy Rezner, San Diego, CA (US); Bahram Valamehr, San Diego, CA (US); Ryan Bjordahl, San Diego, CA (US); and Eigen Peralta, San Diego, CA (US)
Assigned to FATE THERAPEUTICS, INC., San Diego, CA (US)
Filed by Fate Therapeutics, Inc., San Diego, CA (US)
Filed on Jul. 7, 2021, as Appl. No. 17/369,831.
Application 17/369,831 is a division of application No. 16/071,457, granted, now 11,096,964, previously published as PCT/US2017/014408, filed on Jan. 20, 2017.
Claims priority of provisional application 62/336,339, filed on May 13, 2016.
Claims priority of provisional application 62/281,064, filed on Jan. 20, 2016.
Prior Publication US 2021/0393695 A1, Dec. 23, 2021
Int. Cl. A61K 35/17 (2015.01); A61K 31/436 (2006.01); A61K 31/506 (2006.01); A61K 31/7084 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01); C12N 5/0783 (2010.01); G01N 33/50 (2006.01); A61K 38/20 (2006.01)
CPC C12N 5/0646 (2013.01) [A61K 31/436 (2013.01); A61K 31/506 (2013.01); A61K 31/7084 (2013.01); A61K 31/7105 (2013.01); A61K 31/713 (2013.01); A61K 39/4613 (2023.05); A61K 39/464406 (2023.05); A61K 39/464424 (2023.05); A61K 45/06 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C12N 5/0636 (2013.01); G01N 33/505 (2013.01); A61K 38/2086 (2013.01); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2239/55 (2023.05); A61K 2239/59 (2023.05); C12N 2501/06 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2318 (2013.01); C12N 2501/25 (2013.01); C12N 2501/727 (2013.01); C12N 2501/999 (2013.01); C12N 2503/02 (2013.01); Y02A 50/30 (2018.01)] 27 Claims
 
1. A composition comprising immune cells, and at least one agent, wherein:
(a) the immune cells comprise a population of modulated immune cells that are modulated by the at least one agent;
(b) the population of modulated immune cells have improved therapeutic potential in comparison to unmodulated immune cells that are not modulated by the at least one agent;
(c) the at least one agent comprises a GSK3 Inhibitor;
(d) the immune cells are genetically modified to comprise an insertion, a deletion, or a nucleic acid replacement; and
(e) the modulated immune cells comprise NK cells.